GABA
A receptors of the mammalian central nervous system are ligand-gated Cl
- ion channels and the sites of action of many pharmacologically important drugs. GABA
A receptors were characterized using a potent antagonist, [
3H] SR 95531, and agonists such as [
3H] GABA and [
3H] muscimol. Pretreatment of brain membranes with Triton X-100 or phospholipase A
2 increased [
3H] GABA and [
3H] muscimol binding in the frontal cortex and cerebellum, whereas these treatments significantly decreased [
3H] SR 95531 binding. The treatment of rats subacutely with a subconvulsive dose of bicuculline (2 mg/kg, i.p., daily for 10 days) significantly increased the apparent affinity for [
3H]muscimol in the frontal cortex, cerebellum, striatum and substantia nigra. On the other hand, the apparent affinity for [
3H] SR 95531 binding was significantly decreased in these regions. These results suggest that subacute bicuculline treatment in vivo and treatment in vitro of brain membranes with Triton X-100 or phospholipase A
2 bring about a conformational change in the GABA
A-receptor molecule, thus resulting in access increase of the GABA agonist and access decrease of the antagonist to GABA
A receptors. In the cerebellum, the B
max values of [
3H] muscimol and [
3H] SR 95531 binding and V
max value of muscimol-stimulated
36Cl
- uptake were significantly increased following subacute bicuculline treatment with no change in the frontal cortex, with this process involving increased de novo synthesis of GABA
A receptors.
View full abstract